KI-67 AND hTERT Expression Can Aid in the Distinction between Malignant and Benign Pheochromocytoma and Paraganglioma
暂无分享,去创建一个
C. Larsson | M. Bäckdahl | P. Pisa | Dawei Xu | M. Hou | A. Gruber | A. Höög | E. Elder | D. Xu | U. Enberg | E. Elder | M. Bäckdahl | Elisabeth Elder
[1] S. Sheps,et al. Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s) , 1990, World Journal of Surgery.
[2] S. Jansson,et al. Multiple neuroectodermal abnormalities in pheochromocytoma patients , 1988, World Journal of Surgery.
[3] M. Vix,et al. “The” pheochromocytoma: A benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? , 1994, World Journal of Surgery.
[4] A. Höög,et al. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[5] B. Toole,et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer. , 2001, The American journal of pathology.
[6] J. Shay,et al. Telomerase and cancer. , 2001, Human molecular genetics.
[7] T. Nakada,et al. Tumour angiogenesis and Ki‐67 expression in phaeochromocytoma , 2001, BJU international.
[8] P. Heikkilä,et al. Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis. , 2001, The Journal of clinical endocrinology and metabolism.
[9] L. Layfield,et al. Prognostic Value of Immunohistochemical Expression of Topoisomerase Alpha II, MIB-1, p53, E-Cadherin, Retinoblastoma Gene Protein Product, and HER-2/neu in Adrenal and Extra-adrenal Pheochromocytomas , 2000, Applied immunohistochemistry & molecular morphology : AIMM.
[10] H. Bruining,et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? , 2000, The Journal of pathology.
[11] M. Bäckdahl,et al. Gelatinase A, Membrane Type 1 Matrix Metalloproteinase, and Extracellular Matrix Metalloproteinase Inducer mRNA Expression: Correlation with Invasive Growth of Breast Cancer , 2000, World Journal of Surgery.
[12] L. Sobin,et al. Histological Typing of Endocrine Tumours , 2000, International Histological Classification of Tumours.
[13] A. Bamberger,et al. Telomerase activity in benign and malignant adrenal tumors. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[14] M. Demeure,et al. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation , 1999 .
[15] N. Abumrad,et al. Clinical experience over 48 years with pheochromocytoma. , 1999, Annals of surgery.
[16] M. Björkholm,et al. Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms , 1999, British Journal of Cancer.
[17] S. Sukumar,et al. Human Telomerase Reverse Transcriptase ( hTERT ) Gene Expression in Thyroid Neoplasms 1 , 1999 .
[18] H. Bruining,et al. Prognostic value of p53, bcl‐2, and c‐erbB‐2 protein expression in phaeochromocytomas , 1999, The Journal of pathology.
[19] D. Hauri,et al. Pheochromocytomas: can malignant potential be predicted? , 1999, Urology.
[20] C. Larsson,et al. Gelatinase A and Membrane-type 1 Matrix Metalloproteinase mRNA: Expressed in Adrenocortical Cancers but Not in Adenomas , 1999, World Journal of Surgery.
[21] V. Kähäri,et al. Role of thymic peptides as transmitters between the neuroendocrine and immune systems. , 1999 .
[22] V. Kähäri,et al. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. , 1999, Annals of medicine.
[23] Y. Kubota,et al. Elevated levels of telomerase activity in malignant pheochromocytoma , 1998, Cancer.
[24] T. Yoshimoto,et al. The relatively high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas. , 1998, The Journal of endocrinology.
[25] P. Pisa,et al. Telomerase activity and the expression of telomerase components in acute myelogenous leukaemia , 1998, British journal of haematology.
[26] R. Weyant,et al. Prognostic markers in pheochromocytoma. , 1998, Human pathology.
[27] M. Emberton,et al. Changing trends in the management of phaeochromocytoma , 1998, The British journal of surgery.
[28] O. Yoshida,et al. Telomerase activity in adrenal cortical tumors and pheochromocytomas with reference to clinicopathologic features , 1998, Urological Research.
[29] Richard W. Schwartz,et al. Diagnosis and management of pheochromocytoma. , 1998, Current opinion in oncology.
[30] L. Castilla-Guerra,et al. Expression and prognostic value of c‐erbB‐2 oncogene product in human phaeochromocytomas , 1997, Histopathology.
[31] E. Lack. Tumors of the adrenal gland and extra-adrenal paraganglia , 1997 .
[32] P. Hamilton,et al. Flow cytometric analysis does not reliably differentiate benign from malignant phaeochromocytoma , 1996, Clinical endocrinology.
[33] C. Larsson,et al. Stromal Fibroblasts Adjacent to Invasive Thyroid Tumors: Expression of Gelatinase A But Not Stromelysin 3 mRNA , 1996, World Journal of Surgery.
[34] H. Guo,et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. , 1995, Cancer research.
[35] Johannes Gerdes,et al. Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.
[36] J. O'fallon,et al. The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma , 1992, Cancer.
[37] S. Asa,et al. Functional endocrine pathology , 1991 .
[38] M. Schlumberger,et al. Neuropeptide Y and neuron‐specific enolase levels in benign and malignant pheochromocytomas , 1990, Cancer.
[39] M. Israel,et al. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] J. Seltzer,et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. , 1988, The Journal of biological chemistry.
[41] L. Medeiros,et al. Adrenal pheochromocytoma: a clinicopathologic review of 60 cases. , 1985, Human pathology.
[42] H Stein,et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.
[43] A. Tischler,et al. Leu‐enkephalin‐like immunoreactivity in proliferative lesions of the human adrenal medulla and extra‐adrenal paraganglia , 1983, The American journal of surgical pathology.